Table 3 Arterial occlusive events^a.

Variable, n (%)	ASC + NIL (n = 26)		ASC + IMA (n = 25)		ASC + DAS (n = 32)
Variable, n (%)	All grade	Grade ≥ 3	All grade	Grade ≥ 3	All grade	Grade ≥ 3
AOEs, total no. of patients^b	3 (11.5)	1 (3.8)	1 (4.0)	0 (0)	1 (3.1)	0 (0)
Cardiac events	2 (7.7)	1 (3.8)^c	0 (0)	0 (0)	0 (0)	0 (0)
Angina pectoris	2 (7.7)^c	1 (3.8)^c	0 (0)	0 (0)	0 (0)	0 (0)
Cerebrovascular events	2 (7.7)	0 (0)	0 (0)	0 (0)	1 (3.1)	0 (0)
Cerebral arteriosclerosis	1 (3.8)^c	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Cerebrovascular accident	1 (3.8)^c	0 (0)	0 (0)	0 (0)	1 (3.1)	0 (0)
Peripheral arterial occlusive disease	2 (7.7)	1 (3.8)^c	1 (4.0)	0 (0)	0 (0)	0 (0)
Peripheral arterial occlusive disease	2 (7.7)^c	1 (3.8)^c	0 (0)	0 (0)	0 (0)	0 (0)
Embolism arterial	0 (0)	0 (0)	1 (4.0)	0 (0)	0 (0)	0 (0)
Exposure-adjusted AOE rate, n (incidence rate per 100 patient treatment-years)	3 (4.5)		1 (1.2)		1 (1.0)
Cardiac failure (clinical events)	1 (3.8)^d	0 (0)	2 (8.0)^e	0 (0)	1 (3.1)^f	0 (0)

AE adverse event, AOE arterial occlusive event, ASC asciminib, BID twice daily, DAS dasatinib, IMA imatinib, NIL nilotinib, QD once daily.
^aA patient with multiple severity grades for an AE is only counted under the maximum grade. ^bAOEs include the following Medical Dictionary for Regulatory Activities terms: myocardial infarction; embolic and thrombotic events, arterial; ischemic central nervous system vascular conditions; ischemic heart disease. ^cOne patient in the ASC + NIL arm experienced angina pectoris, cerebral arteriosclerosis, cerebrovascular accident, and peripheral arterial occlusive disease. ^dOne patient in the ASC 20 mg BID plus NIL 300 mg BID cohort experienced cardiac failure. ^eOne patient each in the ASC 40 mg BID plus IMA 400 mg QD and ASC 60 mg QD plus IMA 400 mg QD cohorts experienced cardiac failure. ^fOne patient in the ASC 40 mg BID plus DAS 100 mg QD cohort experienced 2 pulmonary edema events.

Search